• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EM - 2类似物在μ阿片受体上的功能选择性

Functional selectivity of EM-2 analogs at the mu-opioid receptor.

作者信息

Piekielna-Ciesielska Justyna, Malfacini Davide, Djeujo Francine Medjiofack, Marconato Chantal, Wtorek Karol, Calo' Girolamo, Janecka Anna

机构信息

Department of Biomolecular Chemistry, Medical University of Lodz, Lodz, Poland.

Department of Pharmaceutical and Pharmacological Sciences, Section of Pharmacology, University of Padova, Padova, Italy.

出版信息

Front Pharmacol. 2023 Feb 24;14:1133961. doi: 10.3389/fphar.2023.1133961. eCollection 2023.

DOI:10.3389/fphar.2023.1133961
PMID:36909169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9998502/
Abstract

The mu opioid receptor agonists are the most efficacious pain controlling agents but their use is accompanied by severe side effects. More recent developments indicate that some ligands can differentially activate receptor downstream pathways, possibly allowing for dissociation of analgesia mediated through the G protein from the opioid-related side effects mediated by β-arrestin pathway. In an effort to identify such biased ligands, here we present a series of thirteen endomorphin-2 (EM-2) analogs with modifications in positions 1, 2, and/or 3. All obtained analogs behaved as mu receptor selective agonists in calcium mobilization assay carried out on cells expressing opioid receptors and chimeric G proteins. A Bioluminescence Resonance Energy Transfer (BRET) approach was employed to determine the ability of analogs to promote the interaction of the mu opioid receptor with G protein or β-arrestin 2. Nearly half of the developed analogs showed strong bias towards G protein, in addition four compounds were nearly inactive towards β-arrestin 2 recruitment while blocking the propensity of EM-2 to evoke mu-β-arrestin 2 interaction. The data presented here contribute to our understanding of EM-2 interaction with the mu opioid receptor and of the transductional propagation of the signal. In addition, the generation of potent and selective mu receptor agonists strongly biased towards G protein provides the scientific community with novel tools to investigate the consequences of biased agonism at this receptor.

摘要

μ阿片受体激动剂是最有效的疼痛控制药物,但其使用伴随着严重的副作用。最近的研究进展表明,一些配体可以差异性地激活受体下游途径,这可能使通过G蛋白介导的镇痛作用与由β-抑制蛋白途径介导的阿片类药物相关副作用相分离。为了鉴定此类偏向性配体,我们在此展示了一系列13种内吗啡肽-2(EM-2)类似物,其在第1、2和/或3位上有修饰。在对表达阿片受体和嵌合G蛋白的细胞进行的钙动员试验中,所有获得的类似物均表现为μ受体选择性激动剂。采用生物发光共振能量转移(BRET)方法来确定类似物促进μ阿片受体与G蛋白或β-抑制蛋白2相互作用的能力。近一半开发的类似物对G蛋白表现出强烈的偏向性,此外,有四种化合物对β-抑制蛋白2的募集几乎无活性,同时阻断了EM-2诱发μ-β-抑制蛋白2相互作用的倾向。本文提供的数据有助于我们理解EM-2与μ阿片受体的相互作用以及信号的转导传播。此外,生成对G蛋白有强烈偏向性的强效和选择性μ受体激动剂为科学界提供了新的工具,以研究该受体上偏向性激动作用的后果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/10789e0ed436/fphar-14-1133961-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/61107a78ca7e/fphar-14-1133961-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/443f94a157dc/fphar-14-1133961-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/70a7a4e0e71b/fphar-14-1133961-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/10789e0ed436/fphar-14-1133961-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/61107a78ca7e/fphar-14-1133961-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/443f94a157dc/fphar-14-1133961-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/70a7a4e0e71b/fphar-14-1133961-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f503/9998502/10789e0ed436/fphar-14-1133961-g004.jpg

相似文献

1
Functional selectivity of EM-2 analogs at the mu-opioid receptor.EM - 2类似物在μ阿片受体上的功能选择性
Front Pharmacol. 2023 Feb 24;14:1133961. doi: 10.3389/fphar.2023.1133961. eCollection 2023.
2
In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH, a mu opioid receptor agonist biased toward β-arrestin.环肽 Dmt-c[d-Lys-Phe-Asp]NH 对μ阿片受体具有激动作用,偏向β-arrestin,体内外活性研究。
Peptides. 2018 Jul;105:51-57. doi: 10.1016/j.peptides.2018.04.014. Epub 2018 Apr 22.
3
Cyclopeptide Dmt-[D-Lys-p-CF-Phe-Phe-Asp]NH, a novel G protein-biased agonist of the mu opioid receptor.环二肽 Dmt-[D-Lys-p-CF-Phe-Phe-Asp]NH,一种新型 μ 阿片受体 G 蛋白偏向激动剂。
Peptides. 2018 Mar;101:227-233. doi: 10.1016/j.peptides.2017.11.020. Epub 2017 Nov 28.
4
MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile.MEL-N16:一系列具有良好镇痛活性和有利副作用特征的新型内吗啡肽类似物。
ACS Chem Neurosci. 2017 Oct 18;8(10):2180-2193. doi: 10.1021/acschemneuro.7b00097. Epub 2017 Aug 10.
5
In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: Acrylfentanyl, Ocfentanyl and Furanylfentanyl.新型芬太尼衍生物:丙烯酰芬太尼、奥芬太尼和呋喃基芬太尼的体外和体内药效学研究。
Neuropharmacology. 2022 May 15;209:109020. doi: 10.1016/j.neuropharm.2022.109020. Epub 2022 Mar 2.
6
Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.新型合成阿片类药物在μ阿片受体的结构-活性关系和偏激动剂评估:使用新型稳定的生物测定平台。
Biochem Pharmacol. 2020 Jul;177:113910. doi: 10.1016/j.bcp.2020.113910. Epub 2020 Mar 14.
7
Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.μ 阿片受体 G 蛋白和β-arrestin 偏向配体联合应用的作用:预防抗伤害性耐受。
Mol Pain. 2017 Jan-Dec;13:1744806917740030. doi: 10.1177/1744806917740030.
8
Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.在寻找更安全的阿片类镇痛药时,偏倚与部分激动作用的比较。
Molecules. 2020 Aug 25;25(17):3870. doi: 10.3390/molecules25173870.
9
The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor.内吗啡肽-1/2 和强啡肽-B 肽在 μ 阿片受体上表现出偏向激动作用。
Pharmacol Rep. 2020 Apr;72(2):465-471. doi: 10.1007/s43440-020-00061-x. Epub 2020 Feb 28.
10
Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist.新型镇痛药塞布诺帕多的药理学特性:一种兼具孤啡肽/痛敏肽和阿片受体激动剂作用的混合性药物
Pharmacol Res Perspect. 2016 Aug 2;4(4):e00247. doi: 10.1002/prp2.247. eCollection 2016 Aug.

引用本文的文献

1
Pathology of pain and its implications for therapeutic interventions.疼痛的病理学及其对治疗干预的影响。
Signal Transduct Target Ther. 2024 Jun 8;9(1):155. doi: 10.1038/s41392-024-01845-w.
2
Peptide-derived ligands for the discovery of safer opioid analgesics.用于发现更安全阿片类镇痛药的肽衍生配体。
Drug Discov Today. 2024 May;29(5):103950. doi: 10.1016/j.drudis.2024.103950. Epub 2024 Mar 20.

本文引用的文献

1
Molecular recognition of morphine and fentanyl by the human μ-opioid receptor.吗啡和芬太尼与人 μ 阿片受体的分子识别。
Cell. 2022 Nov 10;185(23):4361-4375.e19. doi: 10.1016/j.cell.2022.09.041.
2
G protein-coupled receptor interactions with arrestins and GPCR kinases: The unresolved issue of signal bias.G 蛋白偶联受体与阻滞蛋白和 GPCR 激酶的相互作用:信号偏向的未解决问题。
J Biol Chem. 2022 Sep;298(9):102279. doi: 10.1016/j.jbc.2022.102279. Epub 2022 Jul 19.
3
Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands.κ阿片受体药理学:新型检测方法与配体
Front Pharmacol. 2022 Apr 21;13:873082. doi: 10.3389/fphar.2022.873082. eCollection 2022.
4
Community guidelines for GPCR ligand bias: IUPHAR review 32.GPCR 配体偏向的社区准则:IUPHAR 评论 32。
Br J Pharmacol. 2022 Jul;179(14):3651-3674. doi: 10.1111/bph.15811. Epub 2022 Mar 27.
5
Strategies towards safer opioid analgesics-A review of old and upcoming targets.迈向更安全阿片类镇痛药的策略——旧靶点和新靶点的综述。
Br J Pharmacol. 2023 Apr;180(7):975-993. doi: 10.1111/bph.15760. Epub 2022 Jan 21.
6
Data needs and models for the opioid epidemic.阿片类药物流行的数据需求和模型。
Mol Psychiatry. 2022 Feb;27(2):787-792. doi: 10.1038/s41380-021-01356-y. Epub 2021 Oct 29.
7
Pharmacological characterization of naloxegol: In vitro and in vivo studies.纳洛酮醇的药理学特性:体外和体内研究。
Eur J Pharmacol. 2021 Jul 15;903:174132. doi: 10.1016/j.ejphar.2021.174132. Epub 2021 Apr 30.
8
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor.μ-阿片受体 G 蛋白偏向性激动剂的关键性评估。
Trends Pharmacol Sci. 2020 Dec;41(12):947-959. doi: 10.1016/j.tips.2020.09.009. Epub 2020 Oct 20.
9
Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults.oliceridine(TRV130)被批准用于成人中重度疼痛的静脉注射。
Br J Anaesth. 2020 Dec;125(6):e473-e474. doi: 10.1016/j.bja.2020.09.021. Epub 2020 Oct 15.
10
Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.在寻找更安全的阿片类镇痛药时,偏倚与部分激动作用的比较。
Molecules. 2020 Aug 25;25(17):3870. doi: 10.3390/molecules25173870.